Myovant Sciences (NYSE: MYOV) and Argos Therapeutics (NASDAQ:ARGS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a summary of recent ratings and price targets for Myovant Sciences and Argos Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myovant Sciences 0 0 4 0 3.00
Argos Therapeutics 0 3 0 0 2.00

Myovant Sciences currently has a consensus target price of $22.50, indicating a potential upside of 90.19%. Argos Therapeutics has a consensus target price of $1.20, indicating a potential upside of 650.00%. Given Argos Therapeutics’ higher probable upside, analysts plainly believe Argos Therapeutics is more favorable than Myovant Sciences.

Insider and Institutional Ownership

79.2% of Myovant Sciences shares are owned by institutional investors. Comparatively, 18.4% of Argos Therapeutics shares are owned by institutional investors. 2.8% of Myovant Sciences shares are owned by company insiders. Comparatively, 28.2% of Argos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Myovant Sciences and Argos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myovant Sciences N/A -53.75% -48.90%
Argos Therapeutics -13,750.64% -1,532.49% -120.95%

Volatility & Risk

Myovant Sciences has a beta of -2.42, meaning that its share price is 342% less volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.

Earnings and Valuation

This table compares Myovant Sciences and Argos Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myovant Sciences N/A N/A -$83.44 million ($1.41) -8.39
Argos Therapeutics $950,000.00 14.80 -$53.02 million ($1.12) -0.14

Argos Therapeutics has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

About Argos Therapeutics

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.